Drawing for Serial No. 87428273

USPTO serial 87428273

Serial No. 87428273

Reviewed by CopyMark Law Group

Reg. 5510980Status 705Registered
Filing date
Status date
Registration date
Jul 10, 2018
Examiner
MMEJE, OBIEZE GINIKANWA
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 705 means a Madrid-based U.S. registration has accepted Section 71 maintenance and Section 15 incontestability. The U.S. extension is active with strengthened rights. Track next renewal deadlines in TSDR and WIPO records.

Status 705: Status 705 means a Madrid-based U.S. registration has accepted Section 71 maintenance and Section 15 incontestability. The U.S. extension is active with strengthened rights.

Need help with Serial No. 87428273?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Bryant E. Wade/Jessica S. Sachs

Bryant E. Wade/Jessica S. Sachs Harness, Dickey & Pierce, P.L.C.5445 Corporate DriveSuite 200Troy, MI 48098

Goods and services

ClassDescriptionStatusFirst use
005[ Pharmaceutical preparations, namely, acetaminophen, acne medications, ] acne treatment preparations ; [ , adrenal hormone preparations, alcohol for topical use, allergy relief medications, analgesics, androgen preparations, anesthetics for surgical and non-surgical use, antacids, fungicides, antiarrhythmics, antibiotics, anticoagulants, anticonvulsants, antidepressants, antidiabetic preparations, antivirals, anti-cancer preparations, anti-infectives, anti-inflammatories, antipyretic preparations, antibacterial pharmaceuticals, calcium channel blockers, beta blockers, drug delivery agents in the form of dissolvable films that facilitate the delivery of pharmaceutical preparations, drug delivery agents in the form of coatings for tablets that facilitate the delivery of pharmaceutical preparations, eye drops, eye patches for medical purposes, hair growth stimulants, vaccines, adjuvants for use with vaccines, diuretics, amino acids for medical purposes; dietary and nutritional supplements; medicated skin lotions; ] bandages for skin wounds; [ vitamin and mineral preparations for medical use; biological preparations for medical purposes for use in the treatment of the central nervous system, diabetes, skin disorders, wounds, eye diseases and conditions, swelling in the legs, respiratory diseases, asthma, erectile dysfunction, cardiovascular conditions, heart rhythm disorders and infectious diseases; all-purpose disinfecting preparations; pharmaceutical preparations for use in cardiovascular treatment; diagnostic preparations for medical purposes; pharmaceutical preparations for use in chemotherapy; pharmaceutical preparations for the treatment of heart rhythm disorders; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical agents affecting digestive organs; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for treating skin disorders; ] pharmaceutical preparations for treating wounds; [ pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations to prevent swelling in the legs; pharmaceutical preparations for treating respiratory diseases and asthma; pharmaceutical preparations for the treatment of erectile dysfunction; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; plant extracts for pharmaceutical purposes adapted for use in the treatment of the central nervous system, diabetes, skin disorders, wounds, eye diseases and conditions, swelling in the legs, respiratory diseases, asthma, erectile dysfunction, cardiovascular conditions, heart rhythm disorders and infectious diseases; plant extracts for pharmaceutical purposes adapted for use in chemotherapy; veterinary preparations for treatment of intestinal bacteria in mammals; veterinary vaccines; sanitary preparations for medical use; ] medical dressingsACTIVE—
035[ Advertising services; publicity agency services; import-export agency services; sales promotion for others in the field of pharmaceuticals; providing business information in the field of pharmaceuticals; business management assistance in the field of pharmaceuticals; market research; conducting marketing studies; procuring of contracts for the purchase and sale of pharmaceuticals; wholesale and retail store services featuring pharmaceutical and veterinary preparations; wholesale and retail store services featuring dietary supplements; wholesale and retail store services featuring cosmetics; procurement services for others purchasing pharmaceuticals for human and veterinary purposes ]SECTION 8 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Nov 15, 2024NA85NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED—
Nov 15, 2024C15PREGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.—
Nov 15, 2024APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
May 31, 2024E815TEAS SECTION 8 & 15 RECEIVED—
Jul 10, 2023REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Jul 10, 2018R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Apr 19, 2018ISPOWITHDRAWN FROM ISSUE - PETITIONS OFFICE REQUEST—
Apr 17, 2018NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Apr 17, 2018PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Mar 28, 2018NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Mar 12, 2018CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Feb 6, 2018TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Feb 6, 2018CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Feb 1, 2018ALIEASSIGNED TO LIE—
Jan 23, 2018TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 27, 2017GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 27, 2017GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 27, 2017CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 25, 2017DOCKASSIGNED TO EXAMINER—
May 4, 2017CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
May 4, 2017COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
May 4, 2017MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
May 3, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
May 1, 2017NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance